FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to oncology, and relates to the personified administration of targeted therapy agents in patients with metastatic kidney cancer in a preoperative regimen. To do this the activity of proteasomes, calpaines, the content of NF-kB-nuclear factor kB p50, HIF-1α - a factor activated by hypoxia, content of the vascular endothelial growth factor, its receptor, phospho-m-TOR, the MSKCC coefficient, the degree of gradation of the Furman cell differentiation, criterion T and on the basis of the obtained values calculate the discriminant functions Y1, Y2, Y3, Y4 by the formulas. At Y1> Y2, the lack of effect on targeted therapy is predicted, and for Y1 <Y2 - effective targeted therapy is predicted. In case of Y1<Y2, the functions Y3 and Y4 are calculated: for Y3>Y4, targeted therapy with pazopanib is prescribed, and for Y3<Y4, targeted treatment with everolimus is prescribed.
EFFECT: method provides effective antitumor therapy due to individual approach to the choice of targeted therapy.
1 cl, 2 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR EVEROLIMUS THERAPY EFFICIENCY PREDICTION FOR PATIENTS WITH METASTATIC RENAL CANCER | 2016 |
|
RU2616533C1 |
METHOD FOR PREDICTION OF CLINICAL OUTCOME IN PATIENTS WITH METASTATIC KIDNEY CANCER | 2015 |
|
RU2589286C1 |
METHOD FOR PREDICTION OF DEVELOPING HAEMATOGENOUS METASTASES FOLLOWING COMBINED TREATMENT OF KIDNEY CANCER | 2013 |
|
RU2528100C1 |
METHOD FOR PREDICTION OF DEVELOPING LYMPHOGENIC METASTASES IN SQUAMOUS CELL CARCINOMA OF HEAD AND NECK FOLLOWING COMBINATION THERAPY | 2013 |
|
RU2527338C1 |
METHOD FOR PREDICTING THE COURSE OF THE DISEASE IN PATIENTS WITH LOCAL RENAL CELL CARCINOMA OF THE KIDNEY | 2018 |
|
RU2674677C1 |
METHOD FOR PREDICTING THE EFFECTIVENESS OF THE TARGETED THERAPY WITH CETUXIMAB IN THE PATIENTS SUFFERING SQUAMOUS CELL CARCINOMA OF THE TONGUE AND ORAL MUCOSA | 2019 |
|
RU2713453C1 |
METHOD FOR DISTANT METASTASES DEVELOPMENT RISK DEGREE DETERMINATION FOR PATIENTS WITH COLON CANCER | 2016 |
|
RU2623119C1 |
METHOD FOR PREDICTING THE OUTCOME OF A DISEASE IN PATIENTS WITH LUMINAL AND THRICE NEGATIVE BREAST CANCER IN PATIENTS WHO DID NOT RECEIVE CHEMOTHERAPY OR HORMONE THERAPY IN THE NEOADJUVANT REGIMEN | 2017 |
|
RU2648523C1 |
METHOD OF DETERMINING THE RISK OF MALIGNANT TRANSFORMATION OF EPITHELIAL CELLS OF THE LARYNX IN PATIENTS WITH PRECANCEROUS DISEASES OF THE LARYNX | 2022 |
|
RU2803858C1 |
METHOD FOR PREDICTION OF RISK OF DEVELOPING DISTANT METASTASES IN PATIENTS WITH OPERABLE FORMS OF BREAST CANCER WITH METASTASES IN REGIONAL LYMPH NODES | 2020 |
|
RU2733697C1 |
Authors
Dates
2018-04-18—Published
2017-02-13—Filed